Resolution criteria

This market resolves to YES if, before January 1, 2035, credible evidence or authoritative medical consensus officially establishes that BPC-157 is "not recommended" or "advised against" for musculoskeletal injury recovery specifically due to its side effects (such as risks related to angiogenesis, tumor growth stimulation, immunogenicity, or other adverse reactions).

Otherwise, this market resolves to NO.

For the purposes of this market, "evidence indicating it is not recommended" will be satisfied if any of the following occur before January 1, 2035:

1. Clinical Consensus/Guidelines: A major professional orthopedic, sports medicine, or musculoskeletal health organization (such as the American Academy of Orthopaedic Surgeons (AAOS) or equivalent) publishes clinical practice guidelines or consensus statements that explicitly recommend against using BPC-157 for tissue or musculoskeletal repair due to its safety/side-effect profile.

2. Peer-reviewed Clinical Trial/Meta-analysis: A phase II, III, or IV clinical trial (including NCT07437547 or subsequent trials) or a peer-reviewed meta-analysis published in a major medical journal (e.g., NEJM, Lancet, JAMA) concludes that BPC-157's risks/side effects outweigh its therapeutic benefit for musculoskeletal injury recovery, explicitly stating it is "not recommended" or "should not be used" due to safety concerns.

Edge Cases & Notes:

• If there is no such clinical trial conclusion, or guideline published by December 31, 2034, the market will resolve to NO.

• General statements regarding a "lack of safety data" or calling BPC-157 "unapproved" will not count as a recommendation against use due to side effects. There must be active evidence of harm or specific risk-based recommendations against its use.

Background

Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a protein fragment found naturally in human gastric juice. It has gained widespread popularity in biohacking, athletics, and regenerative medicine circles for its purported ability to accelerate the healing of tendons, ligaments, muscles, and other musculoskeletal injuries.

Despite substantial preclinical evidence of tissue repair in rodent models, human clinical evidence remains highly limited. As of 2026, the FDA's Pharmacy Compounding Advisory Committee continues to evaluate its bulk compounding status under Section 503A, and the first major randomized, double-blind Phase II clinical trial (NCT07437547) for acute hamstring muscle strain is recruiting participants.

Safety concerns regarding BPC-157 primarily stem from its mechanism of action. Because it promotes angiogenesis (the formation of new blood vessels) via the upregulation of VEGFR2 pathways, there are theoretical concerns that it could accelerate tumor growth or malignancy. Other concerns raised by the FDA include risks of immunogenicity depending on the administration route, as well as peptide-related impurities in unregulated formulations. This market tracks whether clinical trials or regulatory updates before 2035 will concretely identify side effects that render BPC-157 officially not recommended for musculoskeletal recovery.

This description was generated by AI. Review and verify everything here yourself. You can edit, replace, or delete any part of this description, including the resolution criteria. You do not need to trust the AI output.